PRICEV/ATERHOUSE COOPERS 100

Georgia Tech Facilities, Inc.

Financial Statements June 30, 2003 and 2002

Georgia Tech Facilities, Inc. Consolidated Financial Statements Index June 30, 2003 and 2002

	Page(s)
Report of Independent Auditors	1
Financial Statements	
Statements of Financial Position	2 - 3
Statements of Activities and Changes in Net Assets	4 - 5
Statements of Cash Flows for the Years Ended	6
Notes to the Financial Statements	7 - 11



PricewaterhouseCoopers LLP 10 Tenth Street, Suite 1400 Atlanta GA 30309-3851 Telephone (678) 419 1000 Facsimile (678) 419 1239

Report of Independent Auditors

To the Board of Directors of Georgia Tech Facilities, Inc.

In our opinion, the accompanying statements of financial position and the related statements of activities and changes in net assets and of cash flows present fairly, in all material respects, the financial position of Georgia Tech Facilities, Inc. ("Facilities") at June 30, 2003 and 2002, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of Facilities' management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

Pricewaterhouse Coopers
September 12, 2003

LCP

Georgia Tech Facilities, Inc. Statement of Financial Position June 30, 2003 (in thousands)

	Uni	Unrestricted								Tempo	Temporarily Restricted	stricted										
			Habe	Habersham Building	Wardlaw		Success		Bioengineering Bioscience Complex	Student Athletic Complex	nt tic lex	Technology Square Complex	3, - 5	Student Health Center	A	BME	Re Admi Br	Research Administration Building	H	Family Housing		Total 2003
Accele																						
Cash and cash equivalents	\$	80	\$,		8	•	69			69	296	69	5,731	S	(22)	8	(422)	8	5,663
Investments		290												•				` '				290
Receivable from affiliate		-							•		4,782	15,420	,	•		•				•		20.203
Interest receivable from affiliate				28		87	-1	59						,				•				174
Contribution receivable from affiliate		•		1,726	5,	,293	3,575	75			,			88		3,777		1,253		•		15,712
Net investment in direct financing lease									30,704					•				•				30,704
Construction in process														218		19,603		4,055		493		24,369
Real estate (net of accumulated depreciation		1 400																				
or \$500 in 2003 and \$240 in 2002)		1,498																•				1,498
of accumulated amortization of																						
\$319 in 2003 and \$261 in 2002)				77		237	ĭ	160	945							1		,	١	56		1,475
Total assets	€9	1,869	s	1,831 \$	ς,	,617	\$ 3,794	94 \$	31,649	8	4,782	\$ 15,420	\$ 0	602	S	29,111	89	5,286	65	127	8	100,088
Liabilities and Net Assets																						
Interest payable	69	•	69	28 \$		87 \$	\$	\$ 65	335	55	•		69	•	\$	•	69				69	509
Accounts payable		6							•		4,782	15,420		276		6,111		989		127		27,411
Current portion of bonds payable		•		37		112		92	430		•			•				•				655
Long-term bonds payable		•		1,690	5,	5,181	3,499	66	19,945				,	•				•		•		30,315
Total liablilities		6		1,755	5,	,380	3,634	34	20,710		4,782	15,420		276		6,111		989		127		58,890
Net assets		1,860		76		237	ĭ	160	10,939		i			326		23,000		4,600		'		41,198
Total Liabilities and net assets	€9	1,869	S	1,831 \$,5,	5,617	\$ 3,794	94 \$	31,649	S	4,782	\$ 15,420	8	602	69	29,111	S	5,286	69	127	69	100,088

Georgia Tech Facilities, Inc. Statement of Financial Position June 30, 2002 (in thousands)

	Unr	Unrestricted							Temporarily Restricted	Restrict	pa					1
			Habersham	sham	Wardlaw	Success	Bioel	Bioengineering/ Bioscience	Student	Tec	Fechnology	Student Health	BME	Research Administration		Total
				P	191190	Cellfel	,	Complex	Yaldılloo	,	odnate	Center	Building	Building	8	7007
Assets																
Cash and cash equivalents	69	227	69		•	· &>	69		•	8	92	\$ 1,825	5 \$ 4,375	69	59	6,519
Investments		٠				•			•		•	2,591				8,637
Receivable from affiliates		-				•			37		1,157					1.195
Interest receivable from affiliate				58	88	09		,	•							178
Contributions receivable from affiliate			-	1,761	5,401	3,648		•	•			2,100	0 9,531	4,600		27.041
Net investment in direct financing lease						•		31,376	•							31,376
Construction in process		٠			•	•		•	•			552	2 1,995	252		2.799
Real estate (net of accumulated depreciation of \$240 in 2002 and \$180 in 2001)		1,558			•			,								1 558
Bond issue costs and discounts (net																3
or accumulated amortization of \$261 in 2002 and \$203 in 2001)	€	1		8	246	166		984	,		'					1,476
Total assets	€9	1,786	€	1,870	\$ 5,736	\$ 3,874	\$	32,360	\$ 37	\$	1,249	7,068	3 \$ 21,947	\$ 4,852	69	80,779
Liabilities and Net Assets			•			Č										
Interest payable	€9	•	\$	28	\$ 89	\$ 80	€9	34.	•	49	•	s	&	69	69	520
Accounts payable		က			•	•			37		1,249	343	3 647			2,529
Current portion of bonds payable		٠		35	108	73		410	'							626
Long-term bonds payable				1,726	5,293	3,575		20,375	1		1				- 30	30,969
Total liabilities		8		1,789	5,490	3,708		21,126	37		1,249	343	3 647	252		34,644
Net assets		1,783		18	246	166		11,234				6,725	21,300	4,600		46,135
Total liabilities and net assets	89	1,786	\$	1,870	\$ 5,736	\$ 3,874	8	32,360	\$ 37	\$	1,249	\$ 7,068	3 \$ 21,947	\$ 4,852	€9	80,779

Georgia Tech Facilities, Inc. Statement of Activities and Changes in Net Assets Year Ended June 30, 2003 (in thousands)

	Unrestricted								Tempor	Temporarily Restricted	ted							
								Bioengineering	Student	Technology	ogy	Student	1		Research			
			Habersham	Wa	Wardlaw	Success	•	Bioscience	Athletic	Square	p	Health		BME	Administration	Fa	Family	Total
			Building	3	Center	Center		Complex	Complex	Complex	ex	Center		Building	Building	Ног	Housing	2003
Support from Affiliates	69	·	84	S	265	%	\$ 641	•	٠.	\$		\$ (3	\$ (068)	1,700	•	69		\$ 1,838
Amortization of unearned income from																		
direct financing lease								758							•			758
Interest and dividends	72	288	•					•							•			288
Other income	4	341	•				,	•										341
Net assets released from restriction	7,610	0	(68)		(274)		(185)	(1,053)			1	(6006)	8	1	•		1	
Total revenues	\$ 8,239	39 \$	(5)	S	6)	69	\$ (9)	(295)	S	S	1	\$ (6,399)	\$ (66	1,700	59	٠,	1	\$ 3,225
Interest expense - Habersham Building	69	85 \$		S		69	69	•	9	8		5	٠.		•	4		88
Interest expense - Wardlaw Center	72	262								,						,		262
Interest expense - Success Center	-	177	,				,								٠.			177
Interest expense, net - Bioengineering/Bioscience	0,1	800'1													•			1.008
Depreciation and amortization																		
expense - Habersham Building		63			•										•			63
Amortization expense - Wardlaw Center		10						•										10
Amortization expense - Success Center		7	•												•			7
Amortization expense - Bioengineering/Bioscience		38	•				•	•							•			38
Other financing expense - Habersham Building		-													•			-
Other financing expense - Wardlaw Center		2	•					•							•		,	2
Other financing expense - Success Center		-	•												•			-
Other financing expense - Bioengineering/Bioscience		9						•										9
Contribution of assets to the Institute	600'9	60	•												•			600.9
General and administrative	4	493			1		-1											493
Total expenses	8,162	62						•	•									8.162
Changes in net assets		11	(5)		6		 <u>©</u>	(295)			1	(668'9)	8	1,700			1	(4.937)
Net assets, beginning of year	1,783	8	81		246		99	11,234			1	6,725	8	21,300	4,600		1	46,135
Net assets, end of year	\$ 1,860	\$ 08	76	69	237	\$	\$ 091	10,939	69	S		\$ 3	326 \$	23,000	\$ 4,600	S	,	\$ 41,198

Georgia Tech Facilities, Inc. Statement of Activities and Changes in Net Assets Year Ended June 30, 2002 (in thousands)

	Unre	Unrestricted								Temporarily Restricted	y Restricte	P								-
			l dell	- medenedal	Mondia			1	Bioengineering/	Student			Stuc	Student		Ι.	Research	=		
			Bui	Building	Center	er	Center		Complex	Complex	Square	ology	ě ě	Center	Building	ng .	Administration Building	ation	Total 2002	2 =
Support from Affiliates	45	•	6	88	4	890	187		•	v			e	77.8	6	25		600		6
Amortization of uneamed income from	•		•		•					•	•	•	•							201,00
direct financing lease		•							758					•						758
Interest and dividends		78		•					•			•								78
Net assets released from restriction		1,627		(91)		(278)	(18	(188)	(1,070)							·i				'
Total revenues	49	1,705	49	(3)	\$	(10)	\$	(7)	(312)	5	69	1	\$	6,725	\$ 21	21,300	8	4,600	₩ ₩	33,998
Interest expense - Habersham Building	↔	87	€9		69		€9	69	•	· •	69		69		69		49	'	49	87
Interest expense - Wardlaw Center		266										,		•						286
Interest expense - Success Center		180																		180
Interest expense, net - Bioengineering/Bioscience		1,025		•						•		,		,						1.025
Depreciation and amortization																				
expense - Habersham Building		63				٠.				•		,						,		63
Amortization expense - Wardlaw Center		10								•		,								10
Amortization expense - Success Center		7								•		•								7
Amortization expense - Bioengineering/Bioscience		39							•	•										39
Other financing expense - Habersham Building		-							•							•		,		-
Other financing expenses - Wardlaw Center		2							•			•								2
Other financing expenses - Success Center		-		•					•											-
Other financing expenses - Bioengineering/Bioscience		9							•	•		,								9
General and administrative		202		1				.1						1		•				202
Total expenses		1,889						- I				·i		İ		·i				1,889
Change in net assets		(184)		(3)		(10)		(2)	(312)	•				6,725	21	21,300	4	4,600	35	32,109
Net assets, beginning of year	1	1,967		8		256	17	13	11,546			·		İ		·İ			14	14,026
Net assets, end of year	49	1,783	8	81	₩	246 \$	16	166 \$	11,234	89	49	•	69	6,725	\$ 21	21,300	\$	4,600 \$	46	46,135

Georgia Tech Facilities, Inc. Statements of Cash Flows Years Ended June 30, 2003 and 2002 (in thousands)

Cash flows from operating activities \$ (4,937) \$ 32,109 Adjustments to reconcile change in net assets to net cash provided by operating activities 60 60 Depreciation 60 60 Amortization of bond issue costs 58 58 Urnealized loss on investments 84 8 Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) 732 Decrease in interest receivable from affiliate 11,329 (16,026) Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in interest payable 9 (8) Decrease in interest payable 9 (8) Increase in accounts payable 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (57) - Repayment of bond issue costs (57) - Repayment of Habersh		2003	2002
Adjustments to reconcile change in net assets to net cash provided by operating activities 60 60 Depreciation 60 60 Amortization of bond issue costs 58 58 Unrealized loss on investments 84 8 Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) (732) Decrease in interest receivable 4 2 Decrease in interest framcing lease 672 674 Decrease in interest payable (9) (8) Increase in accounts payable 24,800 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Wardlaw Center debt <td>Cash flows from operating activities</td> <td></td> <td></td>	Cash flows from operating activities		
cash provided by operating activities 60 60 Amortization of bond issue costs 58 58 Unrealized loss on investments 84 8 Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) (732) Decrease in interest receivable 4 2 Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in direct financing lease 672 674 Decrease in interest payable (9) (8) Increase in accounts payable 9 (8) Net cash provided by operating activities 19,142 18,213 Additions to capitalized development cost (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Wardlaw Center deb	Change in net assets	\$ (4,937)	\$ 32,109
Depreciation 60 60 Amortization of bond issue costs 58 58 Unrealized loss on investments 84 8 Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) (732) Decrease in interest receivable 4 2 Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in direct financing lease 672 674 Decrease in interest payable (9) (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (57) - Cash flows from financing activities (57) - Repayment of bond issue costs (57) - Repayment of Wardlaw Center debt (108) (103) Repayment of Wardlaw Center debt (108)<	Adjustments to reconcile change in net assets to net		
Anortization of bond issue costs 58 58 Unrealized loss on investments 84 8 Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) (732) Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in interest payable 672 674 Decrease in interest payable 9 (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (10) (395)	cash provided by operating activities		
Unrealized loss on investments 84 8 Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) (732) Decrease in interest receivable 4 2 Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in interest payable 672 674 Decrease in interest payable 9 (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799 Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Wardlaw Center debt (108) (108) Repayment of Wardlaw Center debt (409) (395) Net cash used in financing acti	Depreciation	60	60
Contribution of assets to the Institute 6,009 - Increase in receivable from affiliates (19,008) (732) Decrease in interest receivable 4 2 Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in direct financing lease 672 674 Decrease in interest payable (9) (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Wardlaw Center debt (108) (103) Repayment of Wardlaw Center debt (409) (395) Net cash used in financing activities (682) (600) (Decreas	Amortization of bond issue costs	58	58
Increase in receivable from affiliates (19,008) (732) Decrease in interest receivable 4 2 Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in direct financing lease 672 674 Decrease in interest payable (9) (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Habersham debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169	Unrealized loss on investments	84	8
Decrease in interest receivable 4 2 Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in direct financing lease 672 674 Decrease in interest payable 9 (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Additions to capitalized development cost (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Wardlaw Center debt (108) (103) Repayment of Wardlaw Center debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169	Contribution of assets to the Institute	6,009	-
Decrease (increase) in contributions receivable from affiliate 11,329 (16,026) Decrease in direct financing lease 672 674 Decrease in interest payable (9) (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350	Increase in receivable from affiliates	(19,008)	(732)
Decrease in direct financing lease 672 674 Decrease in interest payable 99 (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Additions to capitalized development cost (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 8,519	Decrease in interest receivable	4	2
Decrease in interest payable (9) (8) Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities 2(27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 5,563 5,519 Supplemental information Interest paid Habersham Building \$ 86 87 Wardlaw Center 263 <td></td> <td></td> <td>(16,026)</td>			(16,026)
Increase in accounts payable 24,880 2,068 Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities 2(7,579) (2,799) Additions to capitalized development cost (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year (5,519) 350 Cash and cash equivalents, end of year (5,63) 6,519 Supplemental information (5,64) (5,64) </td <td>Decrease in direct financing lease</td> <td>672</td> <td>674</td>	Decrease in direct financing lease	672	674
Net cash provided by operating activities 19,142 18,213 Cash flows from investing activities (27,579) (2,799) Additions to capitalized development cost (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year (57) 350 Cash and cash equivalents, end of year \$ 5,663 6,519 Supplemental information Interest paid 8 8 Habersham Building \$ 86 8		(9)	(8)
Cash flows from investing activities (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year (856) 6,519 Cash and cash equivalents, end of year \$ 5,663 6,519 Supplemental information Interest paid Habersham Building \$ 86 8 7 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 <td< td=""><td>Increase in accounts payable</td><td> 24,880</td><td> 2,068</td></td<>	Increase in accounts payable	 24,880	 2,068
Additions to capitalized development cost (27,579) (2,799) Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year (856) 6,519 Supplemental information Supplemental information 8 8 87 Wardlaw Center 263 266 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Net cash provided by operating activities	 19,142	 18,213
Proceeds from the sale (purchase) of investments 8,263 (8,645) Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year (551) 350 Cash and cash equivalents, end of year \$ 5,663 6,519 Supplemental information Interest paid 8 8 87 Wardlaw Center 263 266 8 266 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Cash flows from investing activities		
Net cash used in investing activities (19,316) (11,444) Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year (57) 350 Cash and cash equivalents, end of year \$ 5,663 6,519 Supplemental information Supplemental information 8 86 87 Wardlaw Center 263 266 266 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Additions to capitalized development cost	(27,579)	(2,799)
Cash flows from financing activities (57) - Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid Habersham Building \$ 86 8 7 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Proceeds from the sale (purchase) of investments	8,263	(8,645)
Payment of bond issue costs (57) - Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid Habersham Building \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Net cash used in investing activities	 (19,316)	 (11,444)
Repayment of Habersham debt (35) (33) Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid Habersham Building \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Cash flows from financing activities		
Repayment of Success Center debt (73) (69) Repayment of Wardlaw Center debt (108) (103) Repayment of Bioengineering Bioscience Complex debt (409) (395) Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid Habersham Building \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Payment of bond issue costs	(57)	-
Repayment of Wardlaw Center debt Repayment of Bioengineering Bioscience Complex debt Repayment of Bioengineering Bioscience Complex debt Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental information Interest paid Habersham Building Habersham Building Safe Success Center 178 Bioengineering/Biosciences Complex (103)	Repayment of Habersham debt	(35)	(33)
Repayment of Bioengineering Bioscience Complex debt(409)(395)Net cash used in financing activities(682)(600)(Decrease) increase in cash and cash equivalents(856)6,169Cash and cash equivalents, beginning of year6,519350Cash and cash equivalents, end of year\$ 5,663\$ 6,519Supplemental informationSupplemental information\$ 86\$ 87Habersham Building\$ 86\$ 87Wardlaw Center263266Success Center178180Bioengineering/Biosciences Complex1,0131,025	Repayment of Success Center debt	(73)	(69)
Net cash used in financing activities (682) (600) (Decrease) increase in cash and cash equivalents (856) 6,169 Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Repayment of Wardlaw Center debt	(108)	(103)
(Decrease) increase in cash and cash equivalents(856)6,169Cash and cash equivalents, beginning of year6,519350Cash and cash equivalents, end of year\$ 5,663\$ 6,519Supplemental informationInterest paidHabersham Building\$ 86\$ 87Wardlaw Center263266Success Center178180Bioengineering/Biosciences Complex1,0131,025	Repayment of Bioengineering Bioscience Complex debt	 (409)	 (395)
Cash and cash equivalents, beginning of year 6,519 350 Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid Habersham Building \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Net cash used in financing activities	(682)	(600)
Cash and cash equivalents, end of year \$ 5,663 \$ 6,519 Supplemental information Interest paid Habersham Building \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	(Decrease) increase in cash and cash equivalents	(856)	6,169
Supplemental information Interest paid Habersham Building Wardlaw Center Success Center Bioengineering/Biosciences Complex Supplemental information \$ 88 \$ 87 87 87 80 100 100 100 100 100	Cash and cash equivalents, beginning of year	6,519	350
Interest paid Habersham Building \$ 86 \$ 87 Wardlaw Center 263 266 Success Center 178 180 Bioengineering/Biosciences Complex 1,013 1,025	Cash and cash equivalents, end of year	\$ 5,663	\$ 6,519
Habersham Building\$ 86\$ 87Wardlaw Center263266Success Center178180Bioengineering/Biosciences Complex1,0131,025	Supplemental information		
Wardlaw Center263266Success Center178180Bioengineering/Biosciences Complex1,0131,025	Interest paid		
Success Center178180Bioengineering/Biosciences Complex1,0131,025	Habersham Building	\$ 86	\$ 87
Bioengineering/Biosciences Complex 1,013 1,025	Wardlaw Center	263	266
	Success Center	178	180
\$ 1,540 \$ 1,558	Bioengineering/Biosciences Complex	1,013	1,025
		\$ 1,540	\$ 1,558

1. Summary of Significant Accounting Policies

Organization

The Georgia Tech Facilities, Inc. ("Facilities") was incorporated in the State of Georgia in 1985 as a not-for-profit corporation. The purpose of Facilities is to construct buildings and other facilities as may be appropriate to meet the needs and goals of the Georgia Institute of Technology (the "Institute"). Financing for construction is obtained by Facilities with debt service funded by support from various sources.

During fiscal year 2000, the Georgia Tech Foundation Facilities, Inc. changed its name to the Georgia Tech Facilities, Inc.

Cash and Cash Equivalents

Facilities considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.

Contributions Received

Facilities accounts for contributions received in accordance with Statement of Financial Accounting Standards No. 116, "Accounting for Contributions Received and Contributions Made," ("SFAS 116"). SFAS 116 requires contributions and unconditional promises to give to be recognized as revenue in the period received at their fair value. Promises to give and gifts received include amounts originally promised or received by affiliated organizations and the Georgia Tech Foundation, Inc. (the "Foundation"). These amounts were restricted by the donors to be used for projects administered by Facilities. Therefore, such promises to give and gifts are transferred to Facilities by the related affiliates.

Long-Lived Assets

Gifts of long-lived assets are reported as restricted support. The restriction expires over the useful life of the donated assets. Buildings are depreciated on a straight-line basis based over a useful life of 20 years.

Investments

Investments consist of marketable securities and bonds. Facilities accounts for its investment securities under the provisions of Statement of Financial Accounting Standards No. 124, "Accounting for Certain Investments Held for Not-for-Profit Organizations" ("SFAS 124"). SFAS 124 requires investments in equity securities with readily determinable fair values and all investments in debt securities to be reported at fair value with unrealized gains and losses included in the Statements of Activities and Changes in Net Assets. As of June 30, 2003 and 2002, unrealized losses of \$84 and \$8, respectively, were included in the Statements of Activities and Changes in Net Assets as Interest and Dividends.

Bond Issue Costs

Bond issue costs directly attributable to securing financing and the related discounts are amortized over the period the bonds are outstanding.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

2. Leasing Arrangements

In connection with the issuance of Series 1997B Bonds, Facilities entered into the following leasing arrangements.

Ground Lease

Facilities leased land on the campus of the Institute from the Board of Regents of the University System of Georgia ("Board of Regents") under a ground lease on which they constructed a new Bioengineering and Biosciences Complex (the "Complex"). The ground lease was signed on November 13, 1997 and has a term from inception until 30 years from the completion of the Complex at a nominal rental cost. Use of the land reverts back to the Board of Regents at the end of the lease term.

Facility Lease

During 1997, Facilities entered into a Facility Lease Agreement with Georgia Tech Research Corporation ("GTRC") whereby Facilities agreed to lease the Complex and to sublease the land on which the Complex is built to GTRC. The Complex was completed in July 1999. Under the 30-year lease arrangement, GTRC's lease payments began on September 1, 1999 and are equal to the debt service, including interest and redemption premiums due, on the 1997B Bonds.

The Complex and the land are leased by GTRC to the Board of Regents. In the event the Complex and land is leased to someone other than the Board of Regents, Facilities is required to pay to the Board of Regents all rentals received over the amount paid under the ground lease.

The following lists the components of the net investment in the direct financing lease as of June 30, 2003 and 2002:

	2003	2002
Total minimum lease payments to be received	\$ 37,122	\$ 38,539
Residual Value	12,300	12,300
Less: Amounts representing estimated executory costs		
included in total minimum lease payments	(83)	(83)
Minimum lease payments receivable	49,339	50,756
Less: Unearned income	(18,635)	(19,380)
Net investment in direct financing lease	\$ 30,704	\$ 31,376

The net investment in direct financing lease included approximately \$773 and \$779 in cash and cash equivalents as of June 30, 2003 and 2002, respectively.

3. Tax Status

Facilities has received a ruling from the Internal Revenue Service that it is exempt from Federal income tax under Section 501(c)(3) of the Internal Revenue Code.

4. Real Estate

A summary of real estate at June 30, 2003 and 2002 follows:

	2003	2002
Land Buildings	\$ 598 1,200	\$ 598 1,200
Less accumulated depreciation	 1,798 (300)	1,798 (240)
	\$ 1,498	\$ 1,558

Depreciation expense for the years ended June 30, 2003 and 2002 amounted to \$60 and \$60, respectively.

5. Bond Issuance

During December 1997, Facilities issued \$11,580 Series 1997A Bonds and \$21,560 Series 1997B Bonds. The Series 1997A Bonds provided funds to repay outstanding Variable Rate Demand Bonds, Series 1992A and 1992B, and to finance the acquisition of a building, known as the Habersham Building, which is located on the campus of the Institute. The Series 1997B Bonds were issued to provide funds to finance the costs of acquisition, construction and installation of the Complex described in Note 2.

The following represents the applicable interest rates and mandatory bond principal redemptions on the Series 1997A Bonds until maturity on September 1, 2027:

Fiscal Year	ncipal nount	Interest Rate
2004	\$ 225	4.30%
2005	235	4.50%
2006	245	4.50%
2007	255	4.60%
2008	270	4.63%
Thereafter	9,365	ranging from 4.75% to 5.00%
	\$ 10,595	

The following represents the applicable interest rates and mandatory bond principal redemptions on the Series 1997B Bonds until maturity on September 1, 2027:

Fiscal year	rincipal mount	Interest Rate
2004	\$ 430	4.30%
2005	450	4.50%
2006	470	4.50%
2007	490	4.60%
2008	515	4.63%
Thereafter	 18,020	ranging from 4.75% to 5.00%
	\$ 20,375	

6. Related Parties

Payment of the principal and related interest and fees on the Series 1997A Bonds has been guaranteed by the Foundation through a Commitment of Support dated as of December 1, 1997. The Foundation is a separate not-for-profit corporation, which was formed in 1932 primarily to raise and receive funds to support the Institute. Certain members of the Board of Directors of Facilities may also serve as trustees of the Foundation.

The guaranteed future bond payments from the Foundation are recorded as contribution receivable in the financial statements in accordance with SFAS 116. The total contribution receivable recorded at June 30, 2003 was \$10,595 on the Series 1997A Bonds and is paid according to the debt schedule above, after the use of any cash held by Facilities. At June 30, 2002, the total contribution receivable was \$10,810 on the Series 1997A Bonds.

Payment of the principal and related interest and fees on the Series 1997B Bonds will be funded by any cash held by Facilities and by lease payments made under the Facility Lease Agreement between Facilities and GTRC. GTRC is a separate not-for-profit corporation founded in 1937 for the purpose of serving Georgia Tech and is operated exclusively for scientific, literary and education purposes, to engage in scientific research, and to distribute and disseminate information resulting from research. In accordance with the Bond Agreement, Facilities has assigned all interests in the Facility Lease Agreement to the Trustee.

On March 27, 2002, Facilities entered into a binding Memorandum of Understanding with the Institute and the Foundation to confirm responsibilities in connection with a \$4,600 project to renovate the Research Administration Building (previously referred to as 505 10th Street), a \$6,725 project to construct a Student Health Center on the campus of the Institute, and a \$23,000 project to construct the Biomedical Engineering building on the campus of the Institute. All of the fundings for these projects is to come from the Foundation and the Institute. During the year ended June 30, 2002, Facilities recognized revenue as Support from Affiliates of \$4,600 related to the Research Administration Building, \$6,725 related to the Student Health Center, and \$21,300 related to the Biomedical Engineering building. During fiscal year 2003, the institute determined that \$390 of the \$6,725 commitment for the Student Health Center would be funded separately through the

operations of the Student Health Center. Accordingly, the facilities reversed the receivable and reduced the support from affiliates by \$390 during the year. In addition, on June 30, 2003, the Facilities transferred the Student Health Center assets totaling \$6,009 to the Board of Regents.

In connection with the above Memorandums of Understanding, the Facilities has entered into Development Management Services Agreements with the Institute under which the Institute has agreed to provide services such as project management and coordination, technical direction, insurance coverage and other services for a fee based on each service. In addition, Facilities will assess a Management Fee of approximately one percent of project costs payable by the Institute and the Foundation.

On December 20, 2002, Facilities entered into a binding Memorandum of Understanding with the Institute to confirm the responsibilities in connection with the financing and construction of the family apartments and related parking facility for the Family Campus Housing project on the campus of the Institute. The Facilities will be responsible for the financing, design, and construction of the \$56,100 project. The Facilities will fund the project through issuance of tax-exempt bonds (see Note 8).

7. Commitments

During fiscal year 2002, Facilities entered into agreements with contractors for the construction of the Student Health Center, the Biomedical Engineering Building, and the renovations to the Research Administration Building. As of June 30, 2003, Facilities' commitments under these agreements are up to \$6,100, \$20,772, and \$4,026, respectively, to be payable as the work is performed. As of June 30, 2003, \$5,824 has been expended for the Student Health Center, \$13,323 for the Biomedical Engineering Building, and \$3,121 for the Research Administration Building.

8. Subsequent Events

During July 2003, Facilities issued \$70,320 Series 2003 Revenue Bonds. The proceeds from these bonds are to be used to finance the construction of the family apartments and related parking facility for the Family Campus Housing project and a parking facility for the Klaus Advanced Computing Building on the campus of the Institute. The Series 2003 Revenue Bonds were issued to provide funds to finance the costs of acquisition, construction, and installation of the above projects.

The following represents the applicable interest rates and mandatory bond principal redemptions on the Series 2003 bonds until maturity on November 1, 2023:

Fiscal Year	rincipal Amount	Interest Rate
2006	\$ 1,435	2.00%
2007	1,805	2.00%
2008	1,845	2.30%
Thereafter	65,235	ranging from 2.63% to 5.25%
	\$ 70,320	